GenVec (GNVC) Gets $590K SBIR Grant from NIAID of NIH

May 3, 2012 7:16 AM EDT
GenVec, Inc. (Nasdaq: GNVC) has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the Company's Respiratory Syncytial Virus (RSV) vaccine program.

The SBIR grant, valued at approximately $590,000, will provide funding to further understand the impact of maternal immunity against RSV on the generation of a protective immune response in newborns. This is an important factor in the development of an effective vaccine for the pediatric population.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News

Add Your Comment